“No evidence of disease,” typically abbreviated as NED, means that a patient’s scans, blood tests, and physical exams show no detectable cancer. It is a clinical status, not a biological guarantee. The phrase describes what today’s tools can see, and those tools have hard limits. A person who reaches NED has cleared an important milestone, but the term carries more nuance than it seems to on the surface, and the gap between “we can’t find it” and “it’s gone forever” is where much of modern oncology focuses its attention.
How NED Differs from Cure and Remission
Oncologists are precise about language, and the terms NED, remission, complete response, and cure all mean slightly different things. NED is a status report at a point in time: right now, available tests detect no cancer. “Complete response” or “complete remission” overlaps heavily with NED and is often used interchangeably in clinical notes, meaning all measurable disease has disappeared on imaging or physical exam. “Partial remission” means the tumor has shrunk substantially but hasn’t vanished. Both terms describe what imaging and lab tests reveal, not what’s happening at the microscopic level.
“Cure” is the word patients most want to hear, and the one doctors are most reluctant to use. Cancer is generally called cured only after enough time has passed that recurrence becomes statistically very unlikely, and that timeline varies by cancer type. Some breast cancers can recur a decade or more after NED is declared, while certain testicular cancers are considered cured after just a few years of clean follow-ups. Because of that variability, most oncologists avoid the word “cure” and stick with NED or remission for years, sometimes indefinitely.
There is also a deeper layer of verification called pathological complete response, or pCR. This applies when tissue is actually removed and examined under a microscope after treatment. A patient might appear to have NED on scans before surgery, but when surgeons remove the tissue, a pathologist can check whether cancer cells are truly absent. In breast cancer, for example, a study of patients who appeared cancer-free on clinical exam found that only about 17% had a confirmed pathological complete response in the breast tissue, while more than half had shown clinical complete response on examination.
The Detection Limits Behind NED
The biggest reason NED doesn’t equal “cancer-free” comes down to physics. Every imaging tool has a minimum size below which it simply cannot see a tumor. CT scans, the workhorse of cancer surveillance, can reliably detect lesions down to about 3 millimeters. MRI has similar limits. PET scanners, which detect metabolic activity rather than structure, have a resolution limit around 4 millimeters and can pick up tumors as small as about 7 millimeters in diameter under favorable conditions.
That sounds impressively small, but a tumor 7 millimeters across already contains millions of cells. Research estimating the theoretical detection limit for PET scanners puts the floor at roughly 100,000 cancer cells under ideal lab conditions, and in a living human body with normal metabolic background activity, the practical threshold climbs higher by about a factor of ten.
Certain cancers are especially tricky for PET. Tumors with low metabolic activity can produce false-negative results, appearing invisible even when they are present. These include some lung cancers like bronchioloalveolar carcinomas, carcinoid tumors, certain kidney and liver cancers, mucinous tumors in the colon, and low-grade lymphomas.
Newer imaging technologies are narrowing these gaps. Prostate-specific membrane antigen (PSMA) PET scans, for instance, are far more sensitive than conventional imaging for prostate cancer. The detection rate is influenced by PSA levels, but PSMA PET catches recurrences at much lower tumor burdens than older methods. Studies have found that a substantial portion of high-risk prostate cancer patients previously classified as non-metastatic by conventional imaging actually harbor metastatic disease that PSMA PET can reveal. Still, even the most advanced scanners have a floor. If cancer cells number in the thousands or low millions and are scattered in small deposits, they are invisible to any imaging modality available today.
Cancer Cells That Survive Undetected
The gap between what imaging can see and what’s biologically present is where dormant cancer cells live. Tumor dormancy is a well-established phenomenon in which small numbers of cancer cells survive treatment by entering a state of growth arrest. These cells stop dividing, which makes them resistant to chemotherapy drugs designed to target rapidly growing cells. They also develop mechanisms to evade the immune system.
Research into the molecular machinery of dormancy has identified specific programs that keep these cells quiet. Certain genes act as dormancy enforcers, pushing cancer cells into a quiescent state and keeping them there for months or years. When those programs break down and the dormancy signals weaken, cells can re-enter the growth cycle and eventually form a detectable recurrence.
The immune system itself plays a complicated role. It can suppress small clusters of surviving cancer cells and hold them in check indefinitely, which is one reason many patients stay in NED permanently. But the immune system can also inadvertently select for cancer cells that are better at hiding from immune surveillance, which increases the danger of the cells that remain.
This dual role means that NED can represent two very different biological realities. In some patients, every last cancer cell truly is gone. In others, a small reservoir of dormant cells persists, kept in check by the immune system or simply too few and too quiet to grow. There is currently no routine clinical test that can distinguish between these two states, though that is changing.
Liquid Biopsies and the Search for Invisible Disease
One of the most active frontiers in oncology is the use of blood-based tests to find what imaging cannot. The concept is called minimal residual disease, or MRD: cancer that persists after treatment but is too small to show up on standard scans or clinical evaluation. Liquid biopsies detect tumor-specific material circulating in the bloodstream, most commonly fragments of tumor DNA known as circulating tumor DNA, or ctDNA.
The clinical appeal is straightforward. If a blood test can detect lingering cancer cells before they grow large enough to appear on a scan, doctors could intervene earlier or, conversely, spare patients from unnecessary ongoing treatment when the blood test comes back clean. A recent analysis of metastatic breast cancer patients who had achieved radiological NED found that about 81% were also MRD-negative on ctDNA testing. But roughly a third of patients had at least one MRD-positive result during follow-up, and in some of those cases, the ctDNA signal flagged disease progression about a month before it became visible on imaging.
In rectal cancer, combining ctDNA results with MRI-based assessments substantially improved the ability to predict whether a patient had truly achieved a complete pathological response after treatment, outperforming either method alone.
These tools are not yet standard of care for most cancers, and interpreting the results remains complicated. A positive ctDNA finding doesn’t always mean the cancer will come roaring back, and a negative one doesn’t guarantee it won’t. But the technology is rapidly moving from research settings into routine clinical use, and it represents the most promising avenue for making NED a more reliable statement about what’s really happening in a patient’s body.
What Surveillance Looks Like After Reaching NED
Once a patient reaches NED, follow-up doesn’t stop. Surveillance typically involves periodic imaging, blood tests for tumor markers, and clinical exams, but the specifics vary widely by cancer type, stage at diagnosis, and treatment history. The goal is to catch any recurrence early enough that it can still be treated effectively.
How often to scan is itself a matter of ongoing research and debate. In early-stage lung cancer treated with surgery, a large study of over 6,000 patients compared high-frequency imaging (scans every three to six months) against lower-frequency surveillance (every six to twelve months). Higher-frequency scanning did not improve recurrence-free survival or overall survival. The researchers concluded that at least annual imaging is warranted, but scanning more often than every six months offered no clear benefit for patients with stage I disease.
The calculus shifts for more advanced or aggressive cancers. A systematic review of post-treatment surveillance in head and neck cancer found strong support for systematic imaging during at least the first one to two years after treatment, reflecting the higher recurrence rates and narrower window for salvage therapy in those cancers.
The appropriate intensity of surveillance is a balancing act. More frequent scanning catches recurrences marginally earlier, but it also means more radiation exposure from CT scans, more false alarms that lead to unnecessary biopsies, and more psychological distress for the patient. Surveillance protocols have gradually shifted toward being tailored by risk rather than following a one-size-fits-all schedule.
How Recurrence Risk Varies by Cancer and Stage
NED after treatment for a stage I colon cancer and NED after treatment for a stage III rectal cancer are very different situations statistically. A large Danish cohort study tracking colorectal cancer patients over time found that five-year recurrence rates ranged from about 7% for stage I colon cancer to roughly 29% for stage III rectal cancer in the most recent treatment era. Patients with more advanced disease also tended to recur sooner after surgery.
Breast cancer introduces another dimension: the risk of late recurrence. In many cancers, the danger period is concentrated in the first two to three years after treatment, and patients who remain NED past that window can feel increasingly confident. But certain breast cancer subtypes, particularly hormone-receptor-positive tumors, carry a meaningful risk of recurrence five, ten, or even fifteen years after initial treatment. A study examining recurrence timing by breast cancer subtype found that late recurrence was a significant predictor of worse overall survival specifically in the luminal B subtype, underscoring how the biology of the tumor shapes the meaning of NED over time.
This variability explains why oncologists set very different follow-up timelines depending on the cancer. A patient who is five years out from a stage I melanoma excision with clean margins has a fundamentally different risk profile than someone five years out from triple-negative breast cancer, even though both carry the same NED label.
Maintenance Therapy While in NED
For some cancers, reaching NED doesn’t mean treatment stops. Maintenance therapy, a lower-intensity treatment given after the main course to keep cancer from returning, is increasingly common in certain settings. In metastatic colorectal cancer, for example, a phase II trial of capecitabine maintenance in patients who had reached NED after first-line treatment reported a three-year disease-free survival rate of about 52% and a three-year overall survival rate of about 84%.
The decision about maintenance therapy involves trade-offs. Continuing treatment carries side effects and costs, and for some patients, the added benefit is modest. For others, particularly those with aggressive cancer types or high-risk features, the evidence supports ongoing treatment to keep dormant cells from waking up. This is another area where the meaning of NED is evolving: it’s increasingly treated as a status to be actively maintained, not just passively observed.
The Emotional Weight of Living with NED
Perhaps the most underappreciated aspect of NED is what it feels like. The phrase sounds like unambiguously good news, and it is, but patients who reach NED often describe a complicated emotional landscape that outsiders don’t expect. The fear of recurrence is pervasive and persistent. In a study of young adult female breast and gynecological cancer survivors, 84% reported clinically meaningful fear of cancer recurrence, and 38% reported severe levels. Virtually every participant experienced some degree of anxiety tied to follow-up scans.
That anxiety has a name in the cancer community: scanxiety. Research in pancreatic cancer survivors found that scanxiety follows a recurring cycle, building in the days and weeks before scheduled surveillance imaging and impacting everyday life. It doesn’t fully resolve between scans; it becomes a background hum that peaks and ebbs but rarely disappears entirely.
A striking finding from an older but still-cited study highlights how much confusion exists around the NED designation itself. Among patients whose physicians had documented NED in their charts, about three-quarters reported that they currently had cancer. These patients experienced levels of distress and impaired functioning similar to patients who actually did have active disease. The researchers noted that some patients may suffer unnecessarily from a lack of understanding about their current disease status, pointing to a significant gap in physician-patient communication.
This disconnect matters practically. Patients who believe they still have active cancer when they are actually in NED may make different decisions about work, relationships, and finances. They may experience chronic stress that affects immune function and overall health. Clearer, more frequent conversations about what NED means, what the surveillance plan is, and what the actual risk numbers look like could meaningfully improve quality of life for people in this liminal space between illness and health.
Unequal Access to the Tools That Define NED
The precision of a NED assessment depends heavily on the quality of the diagnostic tools available, and access to those tools is uneven. Advanced imaging like PET scans is not uniformly available across geographic regions or demographic groups. A Medicare claims study of prostate cancer patients found that those in rural counties were significantly less likely to receive PET imaging compared to patients in metropolitan areas. The disparity was even more pronounced for Black patients in rural settings, who had lower odds of receiving PET scans than either rural White patients or their metropolitan counterparts.
Separate research has confirmed that utilization of advanced imaging in newly diagnosed prostate cancer is significantly lower among Black men compared to White men more broadly. These gaps mean that NED as a clinical status is not defined with equal rigor for every patient. Someone who receives cutting-edge PSMA PET imaging and ctDNA monitoring gets a more granular and reliable NED assessment than someone whose follow-up consists of basic CT scans at longer intervals. The label is the same, but the confidence behind it differs. As newer tools like liquid biopsies become more widely available, ensuring equitable access will be essential to making NED mean the same thing for everyone who receives the designation.